YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer
NCT ID: NCT00050297
Last Updated: 2012-06-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
INTERVENTIONAL
2004-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy
NCT00048659
A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy
NCT01302041
Phase II Study of ASP3550 in Patients With Prostate Cancer
NCT00568516
Phase I/II Study of ASP9521 in Castrate-Resistant Prostate Cancer (CRPC) Patients
NCT01352208
Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
NCT02003924
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
YM598
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma US, Inc.
INDUSTRY
Astellas Pharma Inc
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Clinic AZ
Brussels, , Belgium
University Clinic UCL St. Luc
Brussels, , Belgium
Private Urology Out-patient Ward
Jablonec nad Nisou, , Czechia
Clinic of Urology, University Hospital
Králové, , Czechia
Clinic of Urology, University Hospital
Olomouc, , Czechia
Clinic of Urology, University Hospital
Prague, , Czechia
Hôpital Bichat, service de Urology
Paris, , France
Haingasse 22
Bad Homburg, , Germany
Klinik und Poliklinik für Urologie, Universitätsklinikum Carl-Gustav-Carus
Dresden, , Germany
Klinik u. Poliklinik für Urologie, Philipps Universität, Baldingerstraße
Marburg, , Germany
Krummbogen 15
Marburg, , Germany
Regional Hospital, Department of Urology
Bydgoszcz, , Poland
MedSource Poland
Gdansk, , Poland
Bielanski Hospital, Department of Urology
Warsaw, , Poland
Oncology Center, Department of Urinary Tract Cancer
Warsaw, , Poland
Medical University, Clinic of Urology
Wroclaw, , Poland
Complejo Hospitaliaro Juan Canalejo, Servicio de Urología
Corunna, , Spain
Fundacion Hospital Alcorcón, Servicio Urología
Madrid, , Spain
Hospital Universitario Principe de Asturias, Servicio de Urología, Ctra.
Madrid, , Spain
Department of Urology, Bristol Royal Infirmary
Bristol, , United Kingdom
Department of Urology, Gartnavel Hospital
Glasgow, , United Kingdom
Department of Urology, Norfolk & Norwich Hospital
Norwich, , United Kingdom
Department of Urology, Taunton & Somerset Hospital
Taunton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
598-CL-004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.